Highlights from the 12th National Conference on Anticoagulant Therapy
Journal of Thrombosis and Thrombolysis
Vol. 35, Issue 3, April 2013
Continuing Education Credits Available ONLINE in three easy steps
AMA PRA Category 1 Credits or ANCC Contact Hours available for three selected articles from the 12th National Conference on Anticoagulant Therapy held on May 9-11, 2013, in Phoenix, AZ,
To be awarded a Continuing Education Certificate at no extra charge:
STEP ONE: please read the following three selected articles.
- Assessing Bleeding Risk in Patients Taking Anticoagulants by Marwa Shoeb, MD, MS and Margaret C. Fang, MD, MPH
- Impact of Target-Specific Oral Anticoagulants on Transitions of Care and Outpatient Care Models by Ann Wittkowsky, PharmD, CACP, FASHP, FCCP
- Frequency of Monitoring, Non-Adherence, and Other Topics Dear to an Anticoagulation Clinic Provider by Nathan Clark, PharmD
STEP TWO: Before March 14, 2014 (expiration date)
- Go to www.bucmetest.com and register
- Enter “E.ANTICOAG13” in the Test Code Search field
- 2 results will appear; nurses should select “E.anticoag13 Nurses”
STEP THREE: Complete the online test and evaluation form. If your score is 70% or better you will be able to instantly print out a CME or CNE certificate.
If you have any questions, please contact Boston University School of Medicine, Continuing Medical Education, 72 East Concord Street, A402, Boston, MA 02118, Phone: 617.638.4605, Toll-Free: 800.688.2475, Fax: 617.638.4905, E-mail: email@example.com
Physicians, pharmacists, nurses and associated health professionals who work in the field of anticoagulation.
Educational Needs Addressed
A number of factors require anticoagulation providers to remain vigilant in their knowledge base. Specifically, the indications for anticoagulation therapies have expanded, the use of anticoagulants in special patient populations has increased, and many new antithrombotic therapies are being studied. This conference will deliver the newest research as well as practical, evidence-based information that attendees can apply to their daily practice to enhance the quality of anticoagulation care.
Specific Educational/Learning Objectives
At the conclusion of this conference, participants should be able to:
- Describe the appropriate transition of care for hospital patients on new anticoagulants.
- Describe the correct use of bleeding risk assessment tools
- Report on current issues relating to frequency monitoring, non-compliance and other anticoagulation clinic concerns
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine and the Anticoagulation Forum. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Boston University School of Medicine designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Contact Hours: 2.0
Non-Endorsement of Products
Continuing Nursing Education Provider Unit, Boston University School of Medicine’s provider status refers only to continuing nursing education activities and does not imply that there is real or implied endorsement by Continuing Nursing Education Provider Unit, Boston University School of Medicine or ANCC of any product, service, or company referred to in this activity nor of any company subsidizing costs related to the activity.
Boston University School of Medicine asks all individuals involved in the development of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve any apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
David Garcia, MD, Course Director
Elaine Hylek, MD, MPH, CME Course Director
Terri Schnurr, RN, CCRC, CNE Course Director
Mark Crowther, MD, Committee
Allison Burnett, PharmD, Reviewer
Christina Cove, MD, Reviewer
Christopher Drury, MA, Reviewer
Scott Kaatz, DO, MSC, Reviewer
Sarah O’Brien, MD, MSc, Reviewer
Patti-Ann Collins, PhD, DNP, MSN, MBA, RN, Lead Nurse Planner
Jacalyn Fallman, planner
Elizabeth Goldstein, planner
Jody Walker, MS, planner
Julie White, MS, planner
All Planning, Committee Members, Reviewers (listed above) disclose that they have no relevant financial relationships with any commercial interest except for the following:
- David Garcia, MD, is a consultant for Bristol Myers Squibb /Pfizer, CSL Behring and Daiichi-Sankyo. He receives Grant/Research Support from Bristol Myers Squibb /Pfizer.
- Elaine Hylek, MD, MPH is a consultant for Bayer, Boehringer Ingelheim, Bristol Myers Squibb/Pfizer, Daiichi-Sankyo, and Johnson & Johnson. She receives Grant/Research Support from Bristol Myers Squibb/Pfizer and Johnson & Johnson.
- Mark Crowther, MD, is a consultant for Artisan Pharma, Bayer, Boehringer Ingelheim, Pfizer, and Sanofi Aventis. He receives Grant/Research Support from Leo Laboratories, Octapharma, Pfizer, and Sanofi Aventis. He receives honoraria from Artisan Pharma, Bayer, Leo Laboratories, Organon, and Pfizer. He serves on the Scientific Advisory Board at Alexion and Bayer. He serves on the Speakers Bureau at Bayer, Boehringer Ingelheim, Leo Laboratories, and Pfizer.
- Scott Kaatz, DO, MSC, is a consultant for Bayer/Jansen/Johnson and Johnson, Boehringer Ingelheim, Bristol Myers Squibb and Daiichi Sankyo, Iverson Genetics Diagnostics/Medicare. He receives Grant/Research Support from Bayer/Jansen/Johnson and Johnson, Blue Cross/Blue Shield of Michigan, Boehringer Ingelheim, Bristol Myers Squibb, Eisa, and Iverson Genetics Diagnostics/Medicare. He serves on the Speakers Bureau at Bayer/Jansen/Johnson and Johnson, Boehringer Ingelheim, and GlaxoSmithKline.
- Sarah O’Brien, MD, is a consultant for Bristol Myers Squibb, and receives Grant/Research Support from Ferring Pharmaceuticals.
Nathan Clark, PharmD
Margaret Fang, MD
Marwa Shoeb, MD, MS
Ann Wittkowsky, PharmD, CACP, FASHP, FCCP
All faculty (listed above) disclose that they have no relevant financial relationships with any commercial interest and do not plan on discussing unlabeled/investigational uses of a commercial product.
As of the printing date, this program was supported by an educational grant from Bristol-Myers Squibb and Pfizer, Inc. For current information, please go to www.bucmetest.com and view materials for “E.ANTICOAG13”.
This program was supported by educational grants from Bristol-Myers Squibb and Pfizer, Inc.; CSL Behring; and Daiichi-Sankyo, Inc.
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.
Date of original release: March 15, 2013
Date of expiration: March 14, 2014
Course Code: E.Anticoag13
Estimated time to complete: 2 hours
Jointly sponsored/co-provided by: